Literature DB >> 9406950

Distribution of N-acetylaspartylglutamate immunoreactivity in human brain and its alteration in neurodegenerative disease.

L A Passani1, J P Vonsattel, J T Coyle.   

Abstract

The dipeptide N-acetylaspartylglutamate (NAAG) may be involved in the process of glutamatergic signaling by both acting at glutamate receptors and as a glutamate protransmitter. In the present study we determined the cellular localization and distribution of NAAG-like immunoreactivity (NAAG-LI) in normal human brain and in neurodegenerative disorders to ascertain the degree of NAAG's colocalization to putative glutamatergic pathways. Immunohistochemistry with an antibody against NAAG was performed on control, Huntington's disease (HD) and Alzheimer's disease (AD) human autopsy and biopsy brain sections from the cerebral cortex, hippocampus, amygdala, neostriatum, brainstem and spinal cord. In normal human brain, NAAG-LI was widespread localized to putative glutamatergic pyramidal neurons of the cerebral cortex and hippocampus. Punctate NAAG-LI was present in areas known to receive neuronal glutamatergic input, such as layer IV of the cerebral cortex, striatal neuropil, and the outer portion of the molecular layer of the hippocampal dentate gyrus. In the two pathologic brain regions examined, the HD neostriatum and the AD temporal cortex, we observed a widespread loss of NAAG-LI neurons. In addition NAAG-LI reactive microglia surrounding plaques were seen in AD temporal cortex but not in the HD striatum. Our results suggest that NAAG is substantially localized to putative glutamatergic pathways in human brain and that NAAG-LI neurons are vulnerable to the neurodegenerative process in HD and AD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9406950     DOI: 10.1016/s0006-8993(97)00784-1

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

Review 1.  Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.

Authors:  Joseph T Coyle; Alo Basu; Michael Benneyworth; Darrick Balu; Glenn Konopaske
Journal:  Handb Exp Pharmacol       Date:  2012

Review 2.  Glutamate and schizophrenia: beyond the dopamine hypothesis.

Authors:  Joseph T Coyle
Journal:  Cell Mol Neurobiol       Date:  2006-06-14       Impact factor: 5.046

Review 3.  Genetics and neuropathology of Huntington's disease.

Authors:  Anton Reiner; Ioannis Dragatsis; Paula Dietrich
Journal:  Int Rev Neurobiol       Date:  2011       Impact factor: 3.230

4.  Effect of D-amino acid oxidase activator (DAOA; G72) on brain function during verbal fluency.

Authors:  Diana P Prata; Sergio A Papagni; Andrea Mechelli; Cynthia H Y Fu; Joseph Kambeitz; Marco Picchioni; Fergus Kane; Sridevi Kalidindi; Colm McDonald; Eugenia Kravariti; Timothea Toulopoulou; Elvira Bramon; Muriel Walshe; Robin Murray; David A Collier; Philip K McGuire
Journal:  Hum Brain Mapp       Date:  2011-03-09       Impact factor: 5.038

5.  GCP II (NAALADase) inhibition suppresses mossy fiber-CA3 synaptic neurotransmission by a presynaptic mechanism.

Authors:  Emilio R Garrido Sanabria; Krystyna M Wozniak; Barbara S Slusher; Asaf Keller
Journal:  J Neurophysiol       Date:  2003-08-13       Impact factor: 2.714

Review 6.  Hypothesis-driven medication discovery for the treatment of psychostimulant addiction.

Authors:  Zheng-Xiong Xi; Eliot L Gardner
Journal:  Curr Drug Abuse Rev       Date:  2008-11

7.  Phenotypic characterization of mice heterozygous for a null mutation of glutamate carboxypeptidase II.

Authors:  Liqun Han; Jonathan D Picker; Laura R Schaevitz; Guochuan Tsai; Jiamin Feng; Zhichun Jiang; Hillary C Chu; Alo C Basu; Joanne Berger-Sweeney; Joseph T Coyle
Journal:  Synapse       Date:  2009-08       Impact factor: 2.562

8.  Evidence of NAAG-family tripeptide NAAG2 in the Drosophila nervous system.

Authors:  Emily M Kozik; Elaine M Marzluff; Clark A Lindgren
Journal:  J Neurochem       Date:  2020-09-21       Impact factor: 5.546

9.  Striatal N-Acetylaspartate Synthetase Shati/Nat8l Regulates Depression-Like Behaviors via mGluR3-Mediated Serotonergic Suppression in Mice.

Authors:  Yoshiaki Miyamoto; Noriyuki Iegaki; Kequan Fu; Yudai Ishikawa; Kazuyuki Sumi; Sota Azuma; Kyosuke Uno; Shin-Ichi Muramatsu; Atsumi Nitta
Journal:  Int J Neuropsychopharmacol       Date:  2017-12-01       Impact factor: 5.176

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.